Literature DB >> 11769764

Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?

R Gupta1, M C Raviglione, M A Espinal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769764

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  8 in total

1.  Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India.

Authors:  Kanchan Ajbani; Camilla Rodrigues; Shubhada Shenai; Ajita Mehta
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

2.  Implementation validation performed in Rwanda to determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-resistant Mycobacterium tuberculosis in low-resource countries.

Authors:  Cindy Maria Quezada; Eliane Kamanzi; Julienne Mukamutara; Pim De Rijk; Leen Rigouts; Françoise Portaels; Yanis Ben Amor
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

Review 3.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

4.  Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.

Authors:  Anandi Martin; Juan Carlos Palomino; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 5.  Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.

Authors:  Digby F Warner; Valerie Mizrahi
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

6.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 7.  To control and beyond: moving towards eliminating the global tuberculosis threat.

Authors:  Timothy F Brewer; S Jody Heymann
Journal:  J Epidemiol Community Health       Date:  2004-10       Impact factor: 3.710

8.  Cost-effectiveness of treating multidrug-resistant tuberculosis.

Authors:  Stephen C Resch; Joshua A Salomon; Megan Murray; Milton C Weinstein
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.